IFNG and hemophagocytic syndrome: Despite the increased use of targeted therapies to treat HLH, such as JAK (65), IL-1 (66), IL-6 (67, 68), and IFN-γ inhibitors (69), with a 5-year survival rate of ~60%, there remains a clear need to define the immune cell signaling pathways that contribute to disease.